Profil
Gad Shani is the founder of Thulium Ltd.
He is currently a Professor-Emeritus at Ben-Gurion University of the Negev.
Postes actifs de Gad Shani
| Sociétés | Poste | Début |
|---|---|---|
Thulium Ltd.
 Thulium Ltd. Medical SpecialtiesHealth Technology Thulium Therapy is developing a new radioactive source for Brachytherapy, a cancer treatment modality were a radiation source is inserted into the tumor. The isotope, Thulium 170 (Tm170), is a radioactive variant of the stable metal Tm169. Although the concept of Brachytherapy is not new, much room remains for improvement in order to maximize the probability of completely eliminating a localized tumor while minimizing the radiation damage to the surrounding healthy tissue. | Fondateur | 21/04/2010 |
| Ben-Gurion University of the Negev | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Thulium Ltd.
Thulium Ltd. Medical SpecialtiesHealth Technology Thulium Therapy is developing a new radioactive source for Brachytherapy, a cancer treatment modality were a radiation source is inserted into the tumor. The isotope, Thulium 170 (Tm170), is a radioactive variant of the stable metal Tm169. Although the concept of Brachytherapy is not new, much room remains for improvement in order to maximize the probability of completely eliminating a localized tumor while minimizing the radiation damage to the surrounding healthy tissue. | Health Technology |